 ENGLEWOOD, Colo., March 29, 2021 PRNewswire -- Ampio Pharmaceuticals NYSE American: AMPE, a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the company will present its findings on a poster entitled, Regulatory decisions during COVID-19: Efficient nonclinical inhalation toxicology for a clinical program, at the upcoming 23rd International Congress of the International Society for Aerosols in Medicine ISAM. 